Status:
APPROVED_FOR_MARKETING
Early Access Program of Lazertinib in Republic of Korea
Lead Sponsor:
Yuhan Corporation
Conditions:
Lung Cancer
Eligibility:
All Genders
19+ years
Brief Summary
This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after...
Detailed Description
Lazertinib is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGF...
Eligibility Criteria
Inclusion
- Patients aged at least 19 years
- Patients who have written consent for use of personal and medical information for the study purpose
- Patients who are prescribed and administered with approved indication for Lazerinib in Korea and not been treated with Lazertinib previously.
Exclusion
- Patients with hypersensitivity to Lazertinib or its any ingredients
- Patients who belong to contraindication listed on lazertinib label in Korea
- Patients who are treated for an indication not approved for the use of Lazertinib
- Women who are pregnant or may possibly become pregnant
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04829422
Last Update
March 3 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.